The study will evaluate the safety & efficacy of AC-1204, a ketogenic compound, administered
orally on a daily basis for 6 months. Following the 6 month double-blind phase of the study,
subjects may enroll in an optional 6 month open-label extension phase. Efficacy will be
evaluated by standard tests of memory and cognition, along with other measurements of
activities of daily living and quality of life. Safety will be assessed by frequency of
adverse events and changes in laboratory test results. Subjects will be stratified and
outcomes will be separately analyzed based on apolipoprotein E4 genotype (APOE4).